Literature DB >> 26602778

Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells.

S Kanameishi1, A Otsuka2, Y Nonomura1, A Fujisawa1, Y Endo1, K Kabashima1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26602778     DOI： 10.1093/annonc/mdv580

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

Review 1.  Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Authors:  Petros Fessas; Lucia A Possamai; James Clark; Ella Daniels; Cathrin Gudd; Benjamin H Mullish; James L Alexander; David J Pinato
Journal:  Immunology       Date:  2019-11-19       Impact factor: 7.397

Review 2.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 3.  Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.

Authors:  Atsuto Mouri; Kyoichi Kaira; Ayako Shiono; Y U Miura; Hiroshi Kagamu
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

4.  Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy.

Authors:  Daisuke Tamanoi; Koichi Saruwatari; Kosuke Imamura; Ryo Sato; Takuya Jodai; Shohei Hamada; Yusuke Tomita; Sho Saeki; Shikiko Ueno; Yuji Yonemura; Hidenori Ichiyasu; Takuro Sakagami
Journal:  Intern Med       Date:  2021-11-13       Impact factor: 1.282

5.  Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.

Authors:  Eileen Shiuan; Kathryn E Beckermann; Alpaslan Ozgun; Ciara Kelly; Meredith McKean; Jennifer McQuade; Mary Ann Thompson; Igor Puzanov; John P Greer; Suthee Rapisuwon; Michael Postow; Michael A Davies; Zeynep Eroglu; Douglas Johnson
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

6.  A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma.

Authors:  Claudia Pföhler; Hermann Eichler; Barbara Burgard; Nathalie Krecké; Cornelia S L Müller; Thomas Vogt
Journal:  Transfus Med Hemother       Date:  2017-09-14       Impact factor: 3.747

Review 7.  Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.

Authors:  Hisashi Uhara
Journal:  Int J Clin Oncol       Date:  2018-02-22       Impact factor: 3.850

8.  Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report.

Authors:  Kyoko Inadomi; Hozumi Kumagai; Shuji Arita; Nobuhiro Tsuruta; Kotoe Takayoshi; Koji Mishima; Shun-Ichiro Ota; Mamoru Tanaka; Yuta Okumura; Kosuke Sagara; Kenta Nio; Michitaka Nakano; Hiroshi Uchi; Hidetaka Yamamoto; Hiroshi Ariyama; Hitoshi Kusaba; Hiroaki Niiro; Yoshinao Oda; Koichi Akashi; Eishi Baba
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

9.  Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.

Authors:  Andrew Hantel; Brooke Gabster; Jason X Cheng; Harvey Golomb; Thomas F Gajewski
Journal:  J Immunother Cancer       Date:  2018-07-16       Impact factor: 13.751

10.  Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma.

Authors:  Shinro Hata; Satoki Abe
Journal:  Urol Case Rep       Date:  2020-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.